Clinical Trial

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. This study is being conducted to determine if RAP-219 is safe and effective in participants experiencing mania associated with bipolar I disorder.
Protocol Amendment History 5 changes
critical Enrollment closed, study ongoing 2026-08-11
minor Completion moved earlier: 2026-11 -> 2026-10 2026-08-11
notable Enrollment increased: 224 -> 250 participants 2026-05-13
notable Primary completion moved earlier: 2026-10 -> 2026-09 2026-05-13
minor Completion moved earlier: 2026-12 -> 2026-11 2026-05-13
Trial Details
NCT Number NCT07046494
Lead Sponsor Rapport Therapeutics Inc.
Conditions Bipolar 1 Disorder
Enrollment 253 participants
Start Date 2025-07-25
Primary Completion 2026-08-05 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-10